A Phase 3 Trial of Lesion Network Mapping-Guided cTBS for Motor Recovery After Acute Ischemic Stroke

This Phase 3 study will evaluate whether lesion network mapping-guided continuous theta burst stimulation (cTBS) can improve recovery after acute ischemic stroke. The treatment uses each participant's brain imaging to identify individualized stimulation targets related to stroke symptoms. Participants will receive either active cTBS or a sham procedure in addition to standard stroke care. The study will assess whether this personalized brain stimulation approach improves functional recovery and is safe for patients after ischemic stroke.

Inclusion Criteria: 1. Age 18-80 years. 2. Ischemic stroke onset within the past 14 days. 3. Unilateral, supratentorial ischemic stroke confirmed by CT or MRI. 4. Pre-stroke modified Rankin Scale (mRS) score of 0-1. 5. NIH Stroke Scale (NIHSS) total score 6-25, with item 1a ≤ 1 point, and at least one of items 5a, 5b, 6a, or 6b ≥ 2 points. 6. Written informed consent signed by the patient or the patient's legally authorized representative. Exclusion Criteria: 1. Contraindications to TMS (e.g. cranial metallic foreign bodies, cardiac pacemaker, implanted drug pump, cochlear implant). 2. History of epilepsy or seizure, intracranial hypertension, tumor, or other serious neurological disease. 3. Midline shift or parenchymal mass effect on cranial CT or other imaging. 4. CT or MRI evidence of bilateral acute cerebral infarction or infratentorial acute infarction (brainstem or cerebellum). 5. Evidence of acute intracranial hemorrhage, including spontaneous intracerebral hemorrhage, epidural hematoma, subdural hematoma, intraventricular hemorrhage, or subarachnoid hemorrhage. 6. Pre-stroke mRS ≥ 2. 7. Systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg despite antihypertensive treatment. 8. Pregnant or breastfeeding women, or women planning pregnancy within 90 days. 9. Severe psychiatric disorders or dementia (or other conditions) precluding informed consent or follow-up. 10. Concomitant malignant tumor or severe systemic disease with life expectancy \< 90 days. 11. Participation in any other interventional clinical study within 30 days before randomization, or currently enrolled in such a study.